tert-butyl 4-(1'-methylpropyl)piperidine-1-carboxylate | 651053-92-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(1'-methylpropyl)piperidine-1-carboxylate
• 英文别名: 1-Piperidinecarboxylic acid, 4-(1-methylpropyl)-, 1,1-dimethylethyl ester；tert-butyl 4-butan-2-ylpiperidine-1-carboxylate
• CAS: 651053-92-8
• 化学式: C₁₄H₂₇NO₂
• 分子量: 241.374
• InChiKey: VDKHDPHBJFUHGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-sec-Butyl-4H-pyridine-1-carboxylic acid tert-butyl ester 在 palladium on activated charcoal ammonium formate 作用下， 以 甲醇 为溶剂， 生成 tert-butyl 4-(1'-methylpropyl)piperidine-1-carboxylate
  参考文献：
  名称：

  4-取代氮保护哌啶的高效液相平行合成

  摘要：

  通过CuCN·2LiBr催化的有机锌加成到1-酰基吡啶盐和随后的氢转移氢合成4-取代的N-保护的哌啶的实际条件...

  DOI：

  10.1002/ejoc.200300387

文献信息

• Heterocylic antiviral compounds
  申请人：Lemoine Remy

  公开号：US20080103125A1

  公开（公告）日：2008-05-01

  Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R 1 -R 3 and Ar are as defined herein are antagonists of chemokine CCR 5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR 5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

  化学因子受体拮抗剂，特别是根据公式（I）其中R1-R3和Ar的定义为所定义的3,7-二氮杂双环[3.3.0]辛化合物是化学因子CCR5受体的拮抗剂，可用于治疗或预防人类免疫缺陷病毒（HIV）感染，或治疗艾滋病或ARC。该发明进一步提供了用于治疗通过CCR5拮抗剂缓解的疾病的方法。该发明包括制备公式I化合物的制备方法和用于治疗这些疾病的制药组合物和方法。
• Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10023570B2

  公开（公告）日：2018-07-17

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是通式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• Aryl cyclopropyl-amino-isoquinolinyl amide compounds
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US11312700B2

  公开（公告）日：2022-04-26

  Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.

  本文提供的是芳基环丙基氨基异喹啉酰胺化合物。特别是，本公开提供的化合物可影响细胞中激酶的功能，并可作为治疗剂或与治疗剂一起使用。本公开的化合物可用于治疗多种疾病和病症，包括眼部疾病（如青光眼）、心血管疾病、以异常生长为特征的疾病（如癌症）以及炎症性疾病。本公开进一步提供了含有异喹啉酰胺化合物的组合物。
• DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Arromax Pharmatech Co., Ltd.

  公开号：EP3466943B1

  公开（公告）日：2022-12-28
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array BioPharma, Inc.

  公开号：US20170096425A1

  公开（公告）日：2017-04-06

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3 and X 4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.